PEG 3350 (Transipeg) versus lactulose in the treatment of childhood functional constipation: a double blind, randomised, controlled, multicentre trial
Voskuijl, W.P.; de Lorijn, F.; Verwijs, W.; Hogeman, P; Heijmans, J; Makel, W; Taminiau, J.A.J.M.; Benninga, M.A.

Published in:
Gut

DOI:
10.1136/gut.2004.043620

Citation for published version (APA):
PEG 3350 (Transipeg) versus lactulose in the
treatment of childhood functional constipation: a
double blind, randomised, controlled, multicentre trial

W Voskuijl, F de Lorijn, W Verwijs, P Hogeman, J Heijmans, W Mäkel, J Taminiau and M Benninga

Gut 2004;53;1590-1594
doi:10.1136/gut.2004.043620

Updated information and services can be found at:
http://gut.bmj.com/cgi/content/full/53/11/1590

These include:

References
This article cites 23 articles, 6 of which can be accessed free at:
http://gut.bmj.com/cgi/content/full/53/11/1590#BIBL

4 online articles that cite this article can be accessed at:
http://gut.bmj.com/cgi/content/full/53/11/1590#otherarticles

Email alerting service
Receive free email alerts when new articles cite this article - sign up in the box at the
top right corner of the article.

Topic collections
Articles on similar topics can be found in the following collections

Randomized Controlled Trials: examples (536 articles)
Other Gastroenterology (763 articles)
Children (1796 articles)

Notes

To order reprints of this article go to:
http://www.bmjjournals.com/cgi/reprintform

To subscribe to Gut go to:
http://www.bmjjournals.com/subscriptions/
PEG 3350 (Transipeg) versus lactulose in the treatment of childhood functional constipation: a double blind, randomised, controlled, multicentre trial

W Voskuil, F de Lorijn, W Verwijs, P Hogeman, J Heijmans, W Mäkel, J Taminiau, M Benninga


Despite the fact that childhood constipation is the most common complaint in childhood gastrointestinal disease, no large, placebo controlled, randomised trials are available.1 There is no information concerning the maximum dose, duration, or long term side effects of any compound used in the treatment of childhood constipation. Therefore, treatment of these children is symptomatic and based mainly on clinical experience. It consists of behavioural intervention and oral and sometimes rectal laxatives. The behavioural component includes structured toilet training and keeping a bowel diary.

In the Netherlands, the first line compound is an osmotic laxative such as lactulose. This synthetic disaccharide is fermented by colonic bacteria and results in a decrease in colonic pH, resulting in expansion of faecal volume and acceleration of colonic transit. The action of lactulose is dependent on the colonic microflora, and a large amount of gas is produced as a result of this fermentation, causing bloating and abdominal pain.2-3 Lactulose is also associated with changes in bacterial colonic flora and a subsequent decrease in efficacy with long term use.2

Recently, low dose polyethylene glycols (PEG) have been suggested as alternative treatments for constipation. This non-absorbable compound with a high molecular mass is not metabolised by colonic bacteria and acts by osmosis and volume expansion in the large intestine.4 PEG 3350 appears to be safe as the PEG load recovery in urine is minimal and similar for normal (0.06%) and inflammatory bowel subjects (0.09%).4 PEG electrolyte solutions were successfully and safely used to rapidly clean the colon of adults and children with refractory constipation.4,5 In the long term treatment of constipated adults, PEG was recently shown to be superior to placebo or lactulose with less side effects.6-12 There have been indications that low doses of PEG are also a good alternative in the treatment of constipated children.13-14 However, there are no randomised controlled trials comparing the efficacy of PEG 3350 and lactulose in paediatric constipation. The aim of this study was to compare the clinical efficacy and safety of PEG 3350 (Transipeg; polyethylene glycol with electrolytes) and lactulose in the treatment of functional childhood constipation.

PATIENTS AND METHODS

Patients

Children with constipation were referred by general practitioners, school doctors, and paediatricians. Childhood constipation was defined as having at least two out of four of the following symptoms for the last three months: less than 3 bowel movements per week; encopresis more than once a week; large amounts of stool every 7–30 days (large enough to clog the toilet); and palpable abdominal or rectal mass on physical examination.15 Children aged six month to 15 years were included in this study. Children with organic causes for defecation disorders, including Hirschsprung's disease, spina

Abbreviations: PEG 3350, polyethylene glycol 3350
bifida occulta, or hypothyroidism were excluded from the study.

**Study design**

The study had a two parallel group, double blind, randomised, prospective, multicentre comparative design and was performed in the Academic Medical Centre (AMC) at Emma Children's Hospital, Amsterdam and two non-teaching hospitals also in the Netherlands. The design was approved by the ethics committees of each centre and conducted in compliance with the Helsinki Declaration. Patients were randomly assigned to receive either lactulose (6 g (sachet)) or PEG 3350 (2.95 g (sachet)). Unlabelled numbered boxes with unlabelled sachets were prepared by the AMC pharmacy and handed out to patients after randomisation. The box contained 180 sachets containing either lactulose 6 g per sachet or PEG 3350 2.95 g per sachet.

**Run-in phase**

For one week before the study medication was prescribed, defecation and encopresis frequency, stool consistency, and abdominal pain were recorded. The use of oral laxatives was not allowed during this week. At the end of the week, patients received one enema daily for three days to clear any rectal faecal remains. Subjects <6 years of age received 60 ml Klyx (sodium dioctylsulfosuccinate and sorbitol) while those >6 years of age received 120 ml Klyx. Other recorded baseline characteristics were: feelings of bloating, nausea, vomiting, flatulence, painful defecation, and diarrhoea.

**Treatment phase**

Based on earlier studies and clinical experience,15 16 patients aged between six months and six years of age (inclusive) began treatment with one sachet of either PEG 3350 or lactulose per day (2.95 g or 6 g, respectively) while those older than six years of age were given two sachets per day (5.9 g PEG 3350 or 12 g lactulose). Clinical efficacy and tolerability were recorded in a diary using scores for defecation and encopresis frequency, abdominal pain, feelings of bloating, nausea, vomiting, flatulence, painful defecation, and diarrhoea. Patient assessment of the taste of the treatment was also recorded. Toilet training after each meal (five minutes) was advised and small gifts and praise were used to enhance compliance.

After one week of treatment, efficacy and tolerability, as recorded in the diary, were assessed. If the treatment was considered to be having insufficient effect (persisting symptoms), the dose was increased by one sachet (an additional 2.95 g PEG 3350 or 6 g lactulose). However, if diarrhoea was reported (overdosing) the original dose was reduced by 50% (that is, to one sachet or half a sachet). A stimulant laxative was prescribed if the clinical condition had not improved compared with baseline (not successful) with the maximum amount of laxative sachets per day. Clinical evaluation and assessment of diaries was carried out at enrolment and at 1, 2, 4, and 8 weeks, where treatment dose was also appropriately adjusted (fig 1).

**Follow up**

After the initial double blind phase, patients were asked to continue in an open label assessment for an additional 18 weeks, in which all patients were treated with PEG 3350. Symptoms continued to be recorded in a diary, with outpatient clinical follow up at 4, 8, and 26 weeks after entering the follow up period, providing a total study time of 34 weeks. If patients were unable to visit the outpatient clinic for follow up, history was obtained by telephone.

**Efficacy**

The primary efficacy end points were frequency of stools, frequency of encopresis, and overall treatment success at eight weeks. An increase in defecation frequency was considered to have improved if it rose to three or more times a week while encopresis had to decrease to an incidence of one episode or less every two weeks.

Overall treatment success was defined as three or more bowel movements a week and one encopresis episode or less every two weeks. Stool consistency was also recorded but due to the nature of the parameter and the difficulty in applying semi quantitative values to the categories, statistical analysis of this end point is limited.

**Safety**

The incidence of adverse events during the eight weeks of treatment was also documented. Both the incidence and severity of gastrointestinal adverse events were recorded in the diary and assessed at weeks 1, 2, 4, and 8 of the double blind period of the trial, with a three point scale: 0 = no gastrointestinal symptoms present, 1 = gastrointestinal symptoms present to some extent, and 2 = gastrointestinal symptoms present.

**Statistics**

It was estimated that a total sample of 90 patients would be adequate to show a difference of at least 30% more success at eight weeks using PEG 3350 compared with lactulose, with a two tailed alpha level of 0.05 with a power of 80%. The analysis was performed as a per protocol analysis, including those subjects that completed the double blind treatment period. Values are expressed as mean (SD). Comparisons between the two treatment groups were performed using Student’s t tests or non-parametric Mann-Whitney U tests according to the distribution of values, and χ² tests. A p value of <0.05 was considered significant.

Logistic regression was applied in order to detect variables prognostic for success. The following variables were included in the logistic regression: age at enrolment, number of

---

**Figure 1** Defecation frequency (A) and encopresis frequency (B) in the polyethylene glycol 3350 (PEG) group and lactulose group. There was no significant difference between the two patient groups with respect to these two parameters at all time points. Note: all patients openly switched to PEG 3350 after the study period of eight weeks. FU, follow up.
months treatment before enrolment, composite variable of encopresis and soiling, family history, and sex.

**RESULTS**

Between 1 May 2001 and 1 May 2002, 100 patients (aged 6 months–15 years) with childhood functional constipation were included in the study. The majority of patients (76) were treated in the outpatient clinic of our tertiary hospital; 24 patients were included and treated in the two non-teaching hospitals. As shown in table 1, no significant differences were found with respect to demographic data and recorded baseline characteristics between the two treatment groups. There were nine dropouts due to various reasons (see table 1). Therefore, the final data set consisted of a total of 91 patients (46 in the PEG group and 45 in the lactulose group). As no withdrawals occurred for efficacy reasons, data analysis is based on these 91 patients (per protocol analysis).

**Clinical efficacy at eight weeks**

Compared with intake, a significant increase in mean defecation frequency/week and a significant decrease in mean encopresis frequency/week were found at eight weeks in both groups (table 2). There was no significant difference between the two patient groups with respect to these two parameters at 1, 2, 4, and 8 weeks of the study (see fig 1, table 2). Dividing patients in accordance with age (<6 years and ≥6 years), the same results were found with respect to defecation and encopresis frequency at eight weeks (see table 2).

**Success percentages**

A significantly higher number of patients in the PEG group were successfully treated after eight weeks of treatment compared with the lactulose group (PEG 56% vs lactulose 29%; \( p = 0.02 \)). This difference was irrespective of age (<6 years and ≥6 years). Success rates did not change in the PEG 3350 treatment group during the follow up period (see table 2). In the group of children on lactulose, who openly switched to PEG 3350 at the end of the eight week study period, a significant increase in success rate was found (29% to 47%; \( p = 0.05 \)) after 26 weeks of follow up.

A total of 26 patients were treated with laxatives for at least one year prior to the start of the study. Of these patients, 14% and 33%, respectively, were treated successfully with lactulose or PEG 3350 (NS). In contrast, in those children treated for less than one year, a significant difference in success was found between patients treated with PEG 3350 (63%) or lactulose (31%) (\( p = 0.02 \)).

**Prognostic variables for success**

In multivariate analysis to identify predictors of success, using a logistic regression model, the factors age at enrolment

<table>
<thead>
<tr>
<th>Table 1 Baseline characteristics</th>
</tr>
</thead>
<tbody>
<tr>
<td>PEG 3350</td>
</tr>
<tr>
<td>----------------</td>
</tr>
<tr>
<td>No of patients at randomisation</td>
</tr>
<tr>
<td>Age (y) [mean (SD)]</td>
</tr>
<tr>
<td>Sex (M/F)</td>
</tr>
<tr>
<td>No of patients not withdrawn</td>
</tr>
<tr>
<td>Age (y) [mean (SD)]</td>
</tr>
<tr>
<td>Sex (M/F)</td>
</tr>
</tbody>
</table>

Inclusion criteria (No of patients)

| Defecation frequency <3/week | 32 | 30 |
| Encopresis >1/week | 29 | 30 |
| Large amounts of stool | 30 | 25 |
| Faecal impaction | 24 | 26 |
| Premature withdrawal | 4 | 5 |
| Lost to follow up | 2 | 2 |
| Helicobacter positive | 0 | 2 |
| Reason unknown | 1 | 1 |
| Bad palatability of study medication | 1 | 0 |

PEG, polyethylene glycol 3350.

<table>
<thead>
<tr>
<th>Table 2 Clinical parameters, success percentages, and dosage of laxative (Student’s ( t ) test) in the polyethylene glycol 3350 (PEG) and lactulose groups</th>
</tr>
</thead>
<tbody>
<tr>
<td>PEG 3350</td>
</tr>
<tr>
<td>----------------</td>
</tr>
<tr>
<td>Defecation frequency/week</td>
</tr>
<tr>
<td>Intake</td>
</tr>
<tr>
<td>All age groups</td>
</tr>
<tr>
<td>&lt;6 y</td>
</tr>
<tr>
<td>≥6 y</td>
</tr>
<tr>
<td>Encopresis frequency/week</td>
</tr>
<tr>
<td>Intake</td>
</tr>
<tr>
<td>All age groups</td>
</tr>
<tr>
<td>&lt;6 y</td>
</tr>
<tr>
<td>≥6 y</td>
</tr>
<tr>
<td>Success percentages (95% CI)</td>
</tr>
<tr>
<td>At 8 weeks</td>
</tr>
<tr>
<td>FU 4 weeks</td>
</tr>
<tr>
<td>FU 8 weeks</td>
</tr>
<tr>
<td>FU 26 weeks</td>
</tr>
<tr>
<td>Medication (sachet/day)</td>
</tr>
<tr>
<td>At 8 weeks</td>
</tr>
</tbody>
</table>

FU, follow up; 95% CI, 95% confidence interval.

The lactulose group experienced a significant increase in success after changing to PEG at the end of the intervention period (29%) compared with follow up at 26 weeks (47%) (\( p = 0.03 \)).
and family history did not significantly contribute to success of the treatment. However, the overall success rate after the eight week treatment period was higher in female patients (p = 0.025), lower in children who were treated for more than one year before enrolment in the present study (p = 0.008), and lower in those children with higher frequencies of encopresis at enrolment (p = 0.017).

Side effects
During the eight week study period there were no serious or significant adverse events recorded. Figure 2 shows that significantly more adverse events were reported by patients using lactulose compared with patients on PEG. However, significantly more children complained of bad palatability of PEG compared with those receiving lactulose. This resulted in the premature withdrawal of one patient in the PEG group. Serious side effects were not reported in either group.

Treatment dosage
The mean PEG dosage at four weeks and eight weeks for children who clinically improved was 5.07 (1.36) g/day and 5.40 (2.30) g/day, respectively. In the lactulose group, doses associated with improvement were 11.52 (4.56) g/day (1.9 sachets) and 13.86 (6.66) g/day (2.3 sachets) at four and eight weeks, respectively. Dividing clinically successful patients (after eight weeks) into those <6 years and those ≥6 years, the optimal dose of PEG was 0.26 (0.13) g/kg/day and 0.26 (0.07) g/kg/day, respectively. The optimal dose of lactulose in clinically successful patients <6 years was 0.96 (0.45) g/kg/day and 0.45 (0.27) g/kg/day, respectively.

In the PEG group, mean stool frequency increased by 1.89/week (p = 0.03) after an increase in the dose with one sachet during the clinical visit. No increase in stool frequency was found in the lactulose group after increasing the dose. Nine children in the PEG 3350 group and 10 in the lactulose group needed an additional stimulant laxative (bisacodyl) (NS).

DISCUSSION
In this randomised, controlled, double blind study in children with constipation, we found that compared with baseline, both PEG 3350 and lactulose resulted in a significant increase in defecation frequency and a significant decrease in encopresis frequency after eight weeks of treatment. Clinical improvement was irrespective of age at intake (that is, <6 years and ≥6 years). Follow up at six months showed a comparable increase in defecation frequency and decrease in encopresis frequency in both groups. During the intervention and open label follow up period, these clinical parameters were not significantly different between the two treatment groups.

PEG 3350 however was associated with a significantly higher success rate (56%) than lactulose (29%). Similar success rates for PEG 3350 were found by Loening-Baucke, both after the intervention period and at six months of follow up. Comparison with other paediatric studies using PEG 3350 in the treatment of constipation is difficult as no criteria for success were mentioned in these studies.14 17 A similar success rate for lactulose was reported in an earlier study evaluating the additional effect of biofeedback training (33%) in children with chronic constipation.15 In this latter study, a significant increase in success was found (52%) at six months of follow up compared with the success rate at the end of the intervention period.15 It is unclear if the similar significant increase in success in the group of children who openly switched to PEG 3350 at the end of the eight week study period is the result of PEG 3350 or of our intensive follow up programme.

In accordance with previous studies, a low encopresis frequency and a short period of treatment before enrolment were associated with successful treatment outcome.16 A longer period of treatment suggests an early age of onset of constipation, indicating a primarily organic underlying mechanism, in contrast with children who have shown normal defecation for many years before experiencing constipation. Our study shows that children with encopresis are more difficult to treat, underscoring the necessity of long lasting laxative (oral and/or rectal) treatment. Conflicting data exist concerning the relation between success and relevant cofactors such as sex, positive family history, clinical parameters, anorectal parameters (abnormal contraction of the external sphincter), histological parameters (decreased number of interstitial cells of Cajal, reduced ganglionic density, and size), and symptoms before intake.18-25

In accordance with others who have evaluated PEG 3350 in the treatment of children with constipation, only mild side effects were reported.2 13 14 26 In contrast with an adult study comparing PEG 3350 with lactulose, abdominal pain, straining on defecation, and pain during defecation occurred significantly less often in those children receiving PEG 3350 compared with children receiving lactulose.11 Surprisingly, flatulence did not differ between the two treatment groups, as has been reported by others.10 11 Therefore, mechanisms other than colonic fermentation must also play a role in abdominal pain and production of flatus in these children, such as an osmotic effect or an increase in colonic motility.10 27 28 We have no explanation as to why children receiving lactulose experienced significantly more straining and pain during defecation than children receiving PEG 3350. One can speculate that the dose of lactulose was too low. However, no difference was found in stool consistency or the prevalence of diarrhoea, suggesting an adequate dosage of lactulose.

In the Netherlands, PEG 3350 without electrolytes (Miralax; Braintree Laboratories, Braintree, Massachusetts, USA) is not available. Although a significant number of children did not like the salty taste of PEG 3350, compliance...
was high. Only one child prematurely finished the study because of bad palatability.

The mean effective dose of PEG 3350 for the treatment of constipation in children < 6 years and older than 6 years was 0.26 (0.13) g/kg/day and 0.26 (0.07) g/kg/day, respectively. Although the dose administered was lower than that used in other studies in children with constipation, comparable effects on clinical parameters were found. In contrast with these studies, we used PEG-ELS with additional electrolytes (iso-osmotic), which may exhibit a more potential osmotic effect than PEG without electrolytes (hypo-osmotic).26

In both treatment groups, approximately 20% of patients needed additional stimulant laxatives during the intervention period. This is in contrast with results of Attar and colleagues1 who showed that significantly less (adult) patients with PEG 3350 needed stimulant laxatives (suppositories or micro-enemas) compared with lactulose. For practical purposes, we were not able to prescribe a higher dose, as suggested by others,29 as the maximal amount of PEG 3350 in this study was 8.85 g/day.

In conclusion, the results of this study showed that PEG 3350 was more effective with fewer side effects than lactulose as the first treatment option in children with mild and severe constipation. The optimal dose of PEG 3350 for children younger than six years is 0.26 (0.13) g/kg/day and 0.26 (0.07) g/kg/day for those older than six years.

Authors’ affiliations
W Voskuil, F de Lorijn, J Heijmans, J Taminiou, M Benninga, Department of Paediatric Gastroenterology and Nutrition, Emma Children’s Hospital, Academic Medical Centre, Amsterdam, the Netherlands
W Verwijs, Department of Paediatrics, Hofpoort Ziekenhuis, Woerden, the Netherlands
P Hogeman, Department of Paediatrics, Meander Medisch Centrum, Amersfoort, the Netherlands
W Mäkel, Mediserv BV/Clinical Research facilities BV, Schaijk, the Netherlands

REFERENCES